KLK3 and prostate carcinoma: However, opponents of screening argue that the test has no net benefit and the harms (eg, high false-positive rate, overdetection of insignificant prostate cancer, and biopsy complications) outweigh the benefits demonstrated in randomized clinical trials.27,28,29 However, using MRI as a secondary triage test in men with elevated PSA levels could potentially minimize uncertainties and improve the balance between benefits and harms by reducing the number of false-positive PSA results that would otherwise lead to unnecessary invasive biopsies.